EUCTR2004-004015-38-IT进行中（未招募）不适用
A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertensioHypertensionEUCTR2004-004015-38-DEovartis Pharma Services AG1,100
进行中（未招募）
不适用
A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment in patients with essential hypertensioHypertensionEUCTR2004-004015-38-FIovartis Pharma Services AG1,100
进行中（未招募）
不适用
A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment in patients with essential hypertensioHypertensionEUCTR2004-004015-38-ESovartis Farmacéutica, S.A.1,100
进行中（未招募）
不适用
A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 10 mg in hypertensive patients not adequately responsive to amlodipine 5 mgHypertensionEUCTR2004-002410-11-DKovartis Pharma Services AG504
进行中（未招募）
不适用
A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 10 mg in hypertensive patients not adequately responsive to amlodipine 5 mgHypertensionEUCTR2004-002410-11-DEovartis Pharma Services AG566